November 1, 2012 (Vol. 32, No. 19)
Nodality added Laura A. Brege as president and CEO. Prior to joining Nodality, Brege held senior-level positions at Onyx Pharmaceuticals, including evp and COO. Previously, she was svp and CFO at COR Therapeutics. She also served as CFO at Flextronics and treasurer of The Cooper Companies.
Theorem Clinical Research added Lisa Moore, Ph.D., as associate director of scientific affairs…TiGenix appointed Jean Stéphenne as chairman and Russel Greig, Ph.D., to its board of directors…Althea Technologies promoted Rick Hancock to president and CEO, Chris Duffy to svp of operations, and E.J. Brandreth to svp of quality and regulatory.
Shire Pharmaceuticals hired Frédéric Chereau as svp and franchise lead, angioedema. Before Shire, Chereau was president and CEO of Pervasis Therapeutics. Prior to Pervasis, he was vp and general manager at Genzyme. He began his career with Hemotech where he held sales and marketing positions.
Alliqua added James Sapirstein as CEO…Merz promoted Hyunna Coelho to vp, commercial excellence…VitaPath Genetics appointed Catherine Burzik as chair of its board of directors…Omeros named Arnold C. Hanish to its board of directors…Lightlake Therapeutics added David Kessler, M.D., as strategic advisor…Sigma-Aldrich elected Michael Marberry as director…Igenica hired Mary Haak-Frendscho, Ph.D., as CEO.
Life Technologies promoted Carol Cox to svp of external affairs and corporate communications. Formerly, Cox was vp of investor relations. Cox also served as vp of investor relations at CareFusion and svp of global corporate communications and investor relations at Barr Pharmaceuticals.
Baxter International appointed Uma Chowdhry, Ph.D., and Thomas F. Chen to its board of directors…James Kuo, M.D., is now chairman and CEO at BioSavita…C3 Jian named Richard Bastiani, Ph.D., to its board of directors…Immunovative added Bruce Harmon as CFO…EffRx Pharmaceuticals hired Lorenzo Bosisio as head of business development and marketing…Mission Therapeutics hired Michael Moore, Ph.D., as executive chairman and Fritz Frickel as nonexecutive director.
Karin L. Walker is now vp of finance and chief accounting officer at Affymax. Prior to joining Affymax, Walker served as vp of finance and corporate controller at Amyris and CV Therapeutics. Walker also held senior financial leadership roles at Knight Ridder Digital, Accellion, and Niku.
BioRestorative Therapies named Wayne A. Marasco, M.D., Ph.D., to its scientific advisory board…InVivo Therapeutics added Bill D’Agostino as senior director of manufacturing and engineering…Peter Maag is now president and CEO at XDx…Alan J. Tuchman, M.D., joined Oncolytics Biotech as CMO.
PTC Therapeutics appointed Jerome B. Zeldis, M.D., Ph.D., to its board of directors. Dr. Zeldis is CEO and CMO at Celgene. Previously, he was svp of clinical research and medical affairs. Prior to Celgene, Dr. Zeldis worked at Sandoz and Janssen in clinical research and medical development.
Actinium Pharmaceuticals appointed Hagop Kantarjian, M.D., to its clinical advisory board…Novasep named Patrick Glaser as president and CEO and Roger-Marc Nicoud as non-executive chairman of the board.
Nick Foster joined Optibrium as director of business development. Foster has 20 years of experience within the life science industry and academia. Previously, he worked at BioFocus as associate director, business development Europe, and at Inpharmatica and Medical Research Council U.K.
Linda C. Hogan is now vp, business development at Tolera Therapeutics…Audeo Oncology appointed Leigh Bonney, Susan Kelley, M.D., and David U’Prichard, Ph.D., to its board of directors…Aratana Therapeutics elected Jay Lichter, Ph.D., as chairman and appointed John Vander Vort to its board of directors.
Send your People Announcements to firstname.lastname@example.org